Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo shows promise in lung cancer battle

NCT ID NCT02542293

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This study tested whether a combination of two immunotherapy drugs (durvalumab and tremelimumab) works better than standard chemotherapy for people with advanced non-small cell lung cancer. About 950 adults with stage IV lung cancer who had not received prior treatment took part. The main goal was to see if the drug combination helped people live longer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

953 people

The number who actually took part.

Started

Nov 2015

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 130 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For inclusion in the study, patients should fulfill the following criteria: * Aged at least 18 years * Documented evidence of Stage IV NSCLC * No activating EGFR mutation or ALK rearrangement * No prior chemotherapy or any other systemic therapy for recurrent/metastatic NSCLC * World Health Organization (WHO) Performance Status of 0 or 1 * No Prior exposure to Immune Mediated Therapy (IMT), including, but not limited to, other antiCTLA4, antiPD1, anti PDL1,or antiPDL2 antibodies, excluding therapeutic anticancer vaccines Exclusion Criteria: Patients should not enter the study if any of the following exclusion criteria are fulfilled: * Mixed small cell lung cancer and NSCLC histology, sarcomatoid variant * Brain metastases or spinal cord compression unless the patient is stable (asymptomatic; no evidence of new or emerging brain metastases) and off steroids for at least 14 days prior to start of study treatment. * Active or prior documented autoimmune or inflammatory disorders (e.g., Crohn's disease, ulcerative colitis)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung carcinoma (NSCLC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung carcinoma (NSCLC)

Contacts and locations

Locations

  • Research Site

    Anaheim, California, 92801, United States

  • Research Site

    San Diego, California, 92123, United States

  • Research Site

    Santa Rosa, California, 95403, United States

  • Research Site

    Louisville, Kentucky, 40202, United States

  • Research Site

    Florham Park, New Jersey, 07932, United States

  • Research Site

    Albuquerque, New Mexico, 87102, United States

  • Research Site

    East Setauket, New York, 11733, United States

  • Research Site

    Fresh Meadows, New York, 11366, United States

  • Research Site

    Poughkeepsie, New York, 12601, United States

  • Research Site

    Stony Brook, New York, 11794, United States

  • Research Site

    Canton, Ohio, 44710, United States

  • Research Site

    Columbus, Ohio, 43219, United States

  • Research Site

    Zanesville, Ohio, 43701, United States

  • Research Site

    Pittsburgh, Pennsylvania, 15212, United States

  • Research Site

    Houston, Texas, 77090, United States

  • Research Site

    Berazategui, B1884BBF, Argentina

  • Research Site

    CABA, C1426ANZ, Argentina

  • Research Site

    Ciudad de Buenos Aires, C1025ABI, Argentina

  • Research Site

    Córdoba, 5000, Argentina

  • Research Site

    La Rioja, 5300, Argentina

  • Research Site

    Rosario, S2000KZE, Argentina

  • Research Site

    San Salvador de Jujuy, 4600, Argentina

  • Research Site

    Santa Rosa, 6300, Argentina

  • Research Site

    Barretos, 14784-400, Brazil

  • Research Site

    Belo Horizonte, 30110-022, Brazil

  • Research Site

    Belo Horizonte, 30380-472, Brazil

  • Research Site

    Fortaleza, 60336-045, Brazil

  • Research Site

    Ijuí, 98700-000, Brazil

  • Research Site

    Itajaí, 88301-220, Brazil

  • Research Site

    Porto Alegre, 90035-003, Brazil

  • Research Site

    Porto Alegre, 90160-093, Brazil

  • Research Site

    Porto Alegre, 91350-200, Brazil

  • Research Site

    São José do Rio Preto, 15090-000, Brazil

  • Research Site

    São Paulo, 01221-020, Brazil

  • Research Site

    São Paulo, 01246-000, Brazil

  • Research Site

    São Paulo, 01323 900, Brazil

  • Research Site

    São Paulo, 03102-002, Brazil

  • Research Site

    Plovdiv, 4004, Bulgaria

  • Research Site

    Shumen, 9700, Bulgaria

  • Research Site

    Sofia, 1303, Bulgaria

  • Research Site

    Sofia, 1330, Bulgaria

  • Research Site

    Sofia, 1431, Bulgaria

  • Research Site

    Sofia, 1784, Bulgaria

  • Research Site

    Varna, 9010, Bulgaria

  • Research Site

    Vratsa, 3000, Bulgaria

  • Research Site

    Santiago, 7500713, Chile

  • Research Site

    Santiago, 7500921, Chile

  • Research Site

    Santiago, 7520349, Chile

  • Research Site

    Santiago, 8380456, Chile

  • Research Site

    Santiago, 8420383, Chile

  • Research Site

    Temuco, 4810297, Chile

  • Research Site

    Viña del Mar, 2520612, Chile

  • Research Site

    Beijing, 100142, China

  • Research Site

    Changchun, 130000, China

  • Research Site

    Chongqing, 400030, China

  • Research Site

    Guangzhou, 510100, China

  • Research Site

    Hangzhou, 310022, China

  • Research Site

    Shanghai, 200030, China

  • Research Site

    Shanghai, 200032, China

  • Research Site

    Ürümqi, 830000, China

  • Research Site

    Wuhan, 430022, China

  • Research Site

    Wuhan, 430030, China

  • Research Site

    Odense C, 5000, Denmark

  • Research Site

    Oulu, FI-90029, Finland

  • Research Site

    Tampere, FI-33521, Finland

  • Research Site

    Athens, 115 22, Greece

  • Research Site

    Athens, 11527, Greece

  • Research Site

    Athens, 14564, Greece

  • Research Site

    Heraklion, 71110, Greece

  • Research Site

    Holargos, Athens, 155 62, Greece

  • Research Site

    Ioannina, 45000, Greece

  • Research Site

    Hong Kong, Hong Kong

  • Research Site

    King's Park, 150001, Hong Kong

  • Research Site

    Shatin, 00000, Hong Kong

  • Research Site

    Ahmedabad, 380016, India

  • Research Site

    Bangalore, 560068, India

  • Research Site

    Bangalore, 560076, India

  • Research Site

    Chennai, 600035, India

  • Research Site

    Gurgaon, 122001, India

  • Research Site

    Karamsad, 388325, India

  • Research Site

    New Delhi, 110 085, India

  • Research Site

    Beersheba, 8410101, Israel

  • Research Site

    Jerusalem, 91031, Israel

  • Research Site

    Kfar Saba, 95847, Israel

  • Research Site

    Nahariya, 22100, Israel

  • Research Site

    Petah Tikva, 49100, Israel

  • Research Site

    Ramat Gan, 5265601, Israel

  • Research Site

    Bunkyō City, 160-0023, Japan

  • Research Site

    Fukushima, 960-1295, Japan

  • Research Site

    Habikino-shi, 583-8588, Japan

  • Research Site

    Hirosaki-shi, 036-8545, Japan

  • Research Site

    Iizuka-shi, 820-8505, Japan

  • Research Site

    Iwakuni-shi, 740-8510, Japan

  • Research Site

    Kanazawa, 920-8641, Japan

  • Research Site

    Kishiwada-shi, 596-8501, Japan

  • Research Site

    Kobe, 650-0047, Japan

  • Research Site

    Kurume-shi, 830-0011, Japan

  • Research Site

    Kyoto, 607-8062, Japan

  • Research Site

    Mitaka-shi, 181-8611, Japan

  • Research Site

    Nagaoka-shi, 940-2085, Japan

  • Research Site

    Nagoya, 460-0001, Japan

  • Research Site

    Nagoya, 466-8560, Japan

  • Research Site

    Niigata, 951-8566, Japan

  • Research Site

    Okayama, 700-8607, Japan

  • Research Site

    Osaka, 541-8567, Japan

  • Research Site

    Saga, 840-8571, Japan

  • Research Site

    Sagamihara-shi, 252-0375, Japan

  • Research Site

    Sakaishi, 591-8555, Japan

  • Research Site

    Sendai, 980-0873, Japan

  • Research Site

    Tokushima, 770-8503, Japan

  • Research Site

    Ube-shi, 755-0241, Japan

  • Research Site

    Wakayama, 641-8510, Japan

  • Research Site

    Yokohama, 236-0004, Japan

  • Research Site

    Yokohama, 241-8515, Japan

  • Research Site

    Kuala Lumpur, 59100, Malaysia

  • Research Site

    Kuantan, 25100, Malaysia

  • Research Site

    Kuching, 93586, Malaysia

  • Research Site

    Acapulco, 39670, Mexico

  • Research Site

    Aguascalientes, 20020, Mexico

  • Research Site

    Mérida, 97134, Mexico

  • Research Site

    México, 06100, Mexico

  • Research Site

    México, 14080, Mexico

  • Research Site

    Monterrey, 64710, Mexico

  • Research Site

    Arequipa, AREQUIPA01, Peru

  • Research Site

    Bellavista, CALLAO 2, Peru

  • Research Site

    Lima, 15033, Peru

  • Research Site

    Lima, 41, Peru

  • Research Site

    Lima, L27, Peru

  • Research Site

    Lima, LIMA 34, Peru

  • Research Site

    Lima, LIMA 41, Peru

  • Research Site

    Baguio City, 2600, Philippines

  • Research Site

    Cebu, 6000, Philippines

  • Research Site

    Las Piñas, PH-1704, Philippines

  • Research Site

    Manila, 1000, Philippines

  • Research Site

    Manila, 1003, Philippines

  • Research Site

    Quezon City, 1112, Philippines

  • Research Site

    Bydgoszcz, 85-796, Poland

  • Research Site

    Kielce, 25-734, Poland

  • Research Site

    Krakow, 31-202, Poland

  • Research Site

    Lodz, 93-513, Poland

  • Research Site

    Mrozy, 05-320, Poland

  • Research Site

    Olsztyn, 10-357, Poland

  • Research Site

    Poznan, 60-569, Poland

  • Research Site

    Warsaw, 01-138, Poland

  • Research Site

    Warsaw, 02-781, Poland

  • Research Site

    Wodzisław Śląski, 44-300, Poland

  • Research Site

    Amadora, 2720-276, Portugal

  • Research Site

    Lisbon, 1500-650, Portugal

  • Research Site

    Porto, 4099-001, Portugal

  • Research Site

    Porto, 4100-180, Portugal

  • Research Site

    Porto, 4200-319, Portugal

  • Research Site

    Doha, P.O. Box 3050, Qatar

  • Research Site

    Suceava, 720237, Romania

  • Research Site

    Moscow, 105229, Russia

  • Research Site

    Moscow, 115280, Russia

  • Research Site

    Moscow, 125367, Russia

  • Research Site

    Omsk, 644013, Russia

  • Research Site

    Saint Petersburg, 194291, Russia

  • Research Site

    Saint Petersburg, 197022, Russia

  • Research Site

    Saint Petersburg, 197183, Russia

  • Research Site

    Saint Petersburg, 197342, Russia

  • Research Site

    Saint Petersburg, 197758, Russia

  • Research Site

    Dammam, 31444, Saudi Arabia

  • Research Site

    Riyadh, 11426, Saudi Arabia

  • Research Site

    Riyadh, 12372, Saudi Arabia

  • Research Site

    Singapore, 119228, Singapore

  • Research Site

    Singapore, 217562, Singapore

  • Research Site

    Singapore, 258499, Singapore

  • Research Site

    Singapore, 308433, Singapore

  • Research Site

    Daegu, 41404, South Korea

  • Research Site

    Hwasun-gun, 58128, South Korea

  • Research Site

    Seoul, 05030, South Korea

  • Research Site

    Seoul, 06273, South Korea

  • Research Site

    Seoul, 08308, South Korea

  • Research Site

    Eskilstuna, 63188, Sweden

  • Research Site

    Linköping, 581 85, Sweden

  • Research Site

    Stockholm, 171 64, Sweden

  • Research Site

    Uppsala, 751 85, Sweden

  • Research Site

    Adana, 01120, Turkey (Türkiye)

  • Research Site

    Ankara, 06200, Turkey (Türkiye)

  • Research Site

    Ankara, 06230, Turkey (Türkiye)

  • Research Site

    Ankara, 06280, Turkey (Türkiye)

  • Research Site

    Ankara, 6500, Turkey (Türkiye)

  • Research Site

    Istanbul, 31755, Turkey (Türkiye)

  • Research Site

    Istanbul, 34030, Turkey (Türkiye)

  • Research Site

    Istanbul, 34349, Turkey (Türkiye)

  • Research Site

    Izmir, 35100, Turkey (Türkiye)

  • Research Site

    Chernivtsі, 58013, Ukraine

  • Research Site

    Dnipro, 49102, Ukraine

  • Research Site

    Ivano-Frankivsk, 76018, Ukraine

  • Research Site

    Kapitanivka Village, 08111, Ukraine

  • Research Site

    Kharkiv Region, 61070, Ukraine

  • Research Site

    Kirovohrad, 25006, Ukraine

  • Research Site

    Kyiv, 03115, Ukraine

  • Research Site

    Kyiv, 04107, Ukraine

  • Research Site

    Liutizh, 07352, Ukraine

  • Research Site

    Lviv, 79031, Ukraine

  • Research Site

    Odesa, 65055, Ukraine

  • Research Site

    Sumy, 40022, Ukraine

  • Research Site

    Uzhhorod, 88000, Ukraine

  • Research Site

    Vinnytsia, 21029, Ukraine

  • Research Site

    Guildford, United Kingdom

  • Research Site

    London, EC1M 6BQ, United Kingdom

  • Research Site

    London, NW1 2PG, United Kingdom

  • Research Site

    London, W6 8RF, United Kingdom

  • Research Site

    Manchester, M20 4BX, United Kingdom

  • Research Site

    Metropolitan Borough of Wirral, CH63 4JY, United Kingdom

  • Research Site

    Nottingham, NG5 1PB, United Kingdom

  • Research Site

    Taunton, TA1 5DA, United Kingdom

  • Research Site

    Wolverhampton, WV10 0QP, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.